Article Versions Notes

Zandirad E, Teixeira Farinha H, Barberá-Carbonell B, Geinoz S, Demartines N, Schäfer M, Mantziari S. Neoadjuvant Chemoradiotherapy versus Chemotherapy for Gastroesophageal Junction Adenocarcinoma; Which Is the Optimal Treatment Option? Cancers. 2022; 14(23):5856. https://doi.org/10.3390/cancers14235856

Zandirad, Eric, Hugo Teixeira Farinha, Beatriz Barberá-Carbonell, Sandrine Geinoz, Nicolas Demartines, Markus Schäfer, and Styliani Mantziari. 2022. "Neoadjuvant Chemoradiotherapy versus Chemotherapy for Gastroesophageal Junction Adenocarcinoma; Which Is the Optimal Treatment Option?" Cancers 14, no. 23: 5856. https://doi.org/10.3390/cancers14235856

Zandirad, E., Teixeira Farinha, H., Barberá-Carbonell, B., Geinoz, S., Demartines, N., Schäfer, M., & Mantziari, S. (2022). Neoadjuvant Chemoradiotherapy versus Chemotherapy for Gastroesophageal Junction Adenocarcinoma; Which Is the Optimal Treatment Option? Cancers, 14(23), 5856. https://doi.org/10.3390/cancers14235856